Global Anti Osteoporosis Therapy and Fracture Healing Market 2023-2030

Global Anti Osteoporosis Therapy and Fracture Healing Market 2023-2030

Global Anti Osteoporosis Therapy and Fracture Healing Market Size, Share & Trends Analysis Report by Drug Type (Calcitonin, Bisphosphonates, Hormone Replacement Therapy, Anabolic, and Others), by Route of Administration (Oral and Injectable), and by Distribution Channel (Clinics, Hospital Pharmacies, Drug Stores, Retail Pharmacies, and E-Commerce) Forecast Period (2022-2030)

Global anti osteoporosis therapy and fracture healing market is estimated to grow at a CAGR of 3.0% during the forecast period. A substantial increase in osteoporosis incidence among postmenopausal women due to calcium deficiency drives the market for anti-osteoporosis therapy and fracture healing. Osteoporosis is a chronic and life-threatening disease in which the microstructure of bones is altered due to a reduction in bone mass and bone density. For instance, according to the International Osteoporosis Foundation, it is projected that more than about 50% of all osteoporotic hip fractures will occur in Asia by the year 2050. As per the same source, the annual number of osteoporotic fractures in the European Union is estimated to increase by 1.06 million from 4.28 million in 2019 to 5.34 million in 2034. In addition, the market players which include, Novartis, Orthofix US LLC, OssaTechnics, and others are contributing to the market growth by adopting numero strategies such as partnerships, funding, and mergers, to remain competitive in the global market. In January 2023, The World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) today signed an agreement to develop a strategic roadmap on bone health and ageing and advocate for a public health strategy to prevent fractures among older people.

However, high treatment costs and lack of awareness among the people may hinder the market growth. The total direct cost of osteoporotic fractures in European union countries in 2019 was $57.1 million, according to the International Osteoporosis Foundation.

Segmental Outlook

The global anti osteoporosis therapy and fracture healing market is segmented based on its drug type, route of administration, and distribution channel. Based on its drug type, the market is segmented into calcitonin, bisphosphonates, hormone replacement therapy, anabolic, and others. Based on the route of administration, the market is categorized into oral and injectable. Further, based on the distribution channel, the market is segmented into clinics, hospital pharmacies, drug stores, retail pharmacies, and e-commerce.

The Calcitonin Segment Projected to Rise in the Global Anti Osteoporosis Therapy and Fracture Healing Market

The calcitonin segment is expected to dominate the market. Calcitonin lowers the levels of calcium and phosphate in blood and promotes the bone formation. Increasing cases of osteoporosis globally, coupled with a rise in the Food and drug Administration approval (FDA), drive the segment growth. According to the International Osteoporosis Foundation, over 8.9 million people suffer from osteoporosis globally each year. Moreover, in November 2021, Endo International plc announced that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, and multi-dose vials (2 mL) following final approval from the US Food and Drug Administration. Calcitonin salmon injection is used to treat postmenopausal osteoporosis in women greater than 5 years postmenopause and to treat symptomatic Paget's disease of bone when alternative treatments are not suitable for these conditions.

Regional Outlooks

The global anti osteoporosis therapy and fracture healing market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Based on geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Europe is projected to grow in the anti osteoporosis therapy and fracture healing market. The high prevalence of osteoporosis due to physical inactivity and the rising obese population will likely support the market growth in the Europe region.

Global Anti Osteoporosis Therapy and Fracture Healing Market Growth, by Region 2023-2030

Source: OMR Analysis

The Asia-Pacific Region Leads the Growth of the Global Anti Osteoporosis Therapy and Fracture Healing Market

The Asia-Pacific region is the fastest-growing region in the anti-osteoporosis therapy and fracture healing market. The rising prevalence of osteoporosis is considered to be an important factor driving the market in the Asia-Pacific region. Furthermore, due to the absence of any substitutes such as surgery, the demand for osteoporosis drugs is increasing constantly. According to the International Osteoporosis Foundation, almost 50% of the global bone fracture incidences would occur in the Asia Pacific region by 2050 end. Moreover, in December 2022, the Asia Pacific Consortium on Osteoporosis (APCO) Scientific Summit, to further their vision of reducing the burden of osteoporosis and fragility fractures in the world’s most populous and fastest ageing Asia-Pacific region. The main focus of the summit is to provide education and training to healthcare professionals, enhance research to amass evidence, create national prevention programs; and heighten public awareness and patient support.
\Market Players Outlook
Major companies contributing to the global anti osteoporosis therapy and fracture healing market include GlaxoSmithKline, Medtronic Plc, Merck & Co. Inc., and others. The market players are considerably contributing to the market growth by adopting various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. For instance, the FDA approved abaloparatide, a parathyroid hormone-related peptide analog, to increase bone mineral density among men with osteoporosis at high risk for fracture in December 2022. Abaloparatide (Tymlos, Radius Health) was approved based on the findings from the phase 3 Abaloparatide Treatment for Men (ATOM) study. The FDA approval comes more than 5 years after abaloparatide was approved for postmenopausal women.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global anti osteoporosis therapy and fracture healing market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.